Literature DB >> 34676434

Metabolism of Triglyceride-Rich Lipoproteins.

Jan Borén1,2, Marja-Riitta Taskinen3.   

Abstract

Triglycerides are critical lipids as they provide an energy source that is both compact and efficient. Due to its hydrophobic nature triglyceride molecules can pack together densely and so be stored in adipose tissue. To be transported in the aqueous medium of plasma, triglycerides have to be incorporated into lipoprotein particles along with other components such as cholesterol, phospholipid and associated structural and regulatory apolipoproteins. Here we discuss the physiology of normal triglyceride metabolism, and how impaired metabolism induces hypertriglyceridemia and its pathogenic consequences including atherosclerosis. We also discuss established and novel therapies to reduce triglyceride-rich lipoproteins.
© 2021. The Author(s).

Entities:  

Keywords:  Apolipoprotein B; Chylomicrons; Hypertriglyceridemia; Metabolism; Therapies; Triglyceride-rich lipoproteins (TRL); Very low density lipoproteins (VLDL)

Mesh:

Substances:

Year:  2022        PMID: 34676434     DOI: 10.1007/164_2021_520

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  142 in total

1.  Role of ADP ribosylation factor 1 in the assembly and secretion of ApoB-100-containing lipoproteins.

Authors:  Lennart Asp; Björn Magnusson; Mikael Rutberg; Lu Li; Jan Borén; Sven-Olof Olofsson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-12-23       Impact factor: 8.311

2.  Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

Authors:  M A Austin; M C King; K M Vranizan; R M Krauss
Journal:  Circulation       Date:  1990-08       Impact factor: 29.690

3.  Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity.

Authors:  Martin Adiels; Niina Matikainen; Jukka Westerbacka; Sanni Söderlund; Thomas Larsson; Sven-Olof Olofsson; Jan Borén; Marja-Riitta Taskinen
Journal:  Atherosclerosis       Date:  2012-02-07       Impact factor: 5.162

Review 4.  Diabetic dyslipidaemia.

Authors:  Martin Adiels; Sven-Olof Olofsson; Marja-Riitta Taskinen; Jan Borén
Journal:  Curr Opin Lipidol       Date:  2006-06       Impact factor: 4.776

5.  Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia.

Authors:  Martin Adiels; Marja-Riitta Taskinen; Elias Björnson; Linda Andersson; Niina Matikainen; Sanni Söderlund; Juhani Kahri; Antti Hakkarainen; Nina Lundbom; Carina Sihlbom; Annika Thorsell; Haihong Zhou; Kirsi H Pietiläinen; Chris Packard; Jan Borén
Journal:  Diabetes Obes Metab       Date:  2019-05-08       Impact factor: 6.577

Review 6.  Molecular mechanisms of apolipoprotein B mRNA editing.

Authors:  S Anant; N O Davidson
Journal:  Curr Opin Lipidol       Date:  2001-04       Impact factor: 4.776

7.  A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions.

Authors:  Martin Adiels; Chris Packard; Muriel J Caslake; Philip Stewart; Aino Soro; Jukka Westerbacka; Bernt Wennberg; Sven-Olof Olofsson; Marja-Riitta Taskinen; Jan Borén
Journal:  J Lipid Res       Date:  2004-10-16       Impact factor: 5.922

8.  Overproduction of large VLDL particles is driven by increased liver fat content in man.

Authors:  M Adiels; M-R Taskinen; C Packard; M J Caslake; A Soro-Paavonen; J Westerbacka; S Vehkavaara; A Häkkinen; S-O Olofsson; H Yki-Järvinen; J Borén
Journal:  Diabetologia       Date:  2006-02-04       Impact factor: 10.122

9.  Apoprotein B-100 production is decreased in subjects heterozygous for truncations of apoprotein B.

Authors:  C A Aguilar-Salinas; P H Barrett; K G Parhofer; S G Young; D Tessereau; J Bateman; C Quinn; G Schonfeld
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-01       Impact factor: 8.311

10.  Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Tracey J Brown; Julii S Brainard; Priti Biswas; Gabrielle C Thorpe; Helen J Moore; Katherine Ho Deane; Carolyn D Summerbell; Helen V Worthington; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2020-02-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.